From: Combination strategies to maximize the benefits of cancer immunotherapy
Cancer | Line of therapy | Targeted therapy | Immunotherapy | Clinical benefit | Statistics | Trial name and reference |
---|---|---|---|---|---|---|
Kidney cancer | Metastatic, 1st line | Axitinib | Pembrolizumab | 12-Mo OS: 89.9% versus 78.3% | HR 0.53; 95% CI 0.38 to 0.74; P < 0.0001 | KEYNOTE-426, [301] |
Kidney cancer | Metastatic, 1st line | Cabozantinib | Nivolumab | PFS 16.6 versus 8.3 | HR 0.51; 95% CI 0.41 to 0.64; P < 0.001 | CheckMate -9ER, [303] |
Kidney cancer | Metastatic, 1st line | Axitinib | Avelumab | PFS 13.8 versus 7.2 mos, | HR 0.61; 95% CI, 0.47 to 0.79; P < 0.001 | JAVELIN Renal 101, [302] |
Endometrial cancer not MSI-H or dMMR | Metastatic, salvage | Lenvatinib | Pembrolizumab | ORR of 38.3% (95% CI, 29–49%) | Single-arm trial | KEYNOTE-146, [306] |
Hepatocellular carcinoma | Unresectable, 1st line | Bevacizumab | Atezolizumab | 12-mo OS: 67.2% versus 54.6% for sorafenib | HR 0.58; 95% CI 0.42 to 0.79; P < 0.001 | IMbrave150, [309] |
BRAF V600( +) advanced melanoma | Advanced, 1st line | Vemurafenib + cobimetinib | Atezolizumab | PFS 15.1 versus 10.6 mo | HR 0·78; 95% CI 0·63–0·97; p = 0·025 | IMspire150, [313] |